Investor Relations

Webcast ImageWebcast
Depomed at Biotechnology Industry Organization CEO & Investor Conference (Live)
02/09/10 at 10:30 a.m. ET

Depomed, Inc., headquartered in Menlo Park, California, was founded in August 1995 and became a publicly traded company on the Nasdaq National Market in November 1997 under the ticker symbol, DEPO.

Depomed’s policy is to fully comply with all rules put forth by the Securities and Exchange Commission and the Nasdaq National Market. For misplaced stock certificates, please contact our transfer agent, Continental Stock Transfer, directly.

RECENT NEWSMore >>
DateTitle 
02/02/10Depomed to Present at the 12th Annual BIO CEO & Investor ConferencePrinter Friendly Version
02/01/10Depomed Announces Allowance of U.S. Patent Covering Gastric Retentive Gabapentin Dosage FormsPrinter Friendly Version
01/21/10Depomed Announces Receipt of $500,000 Milestone Payment from Covidien for the Development of a Second FormulationPrinter Friendly Version
STOCKHOLDER INFORMATION
Transfer Agent
Continental Stock Transfer & Trust Co.
17 Battery Place
New York, NY 10004
Phone: (212) 509-4000 ext. 206
Investor Relations
Sheilah Serradell
Phone: 650.462.5900
investors@depomed.com
Independent Registered Public Accounting Firm
Ernst & Young LLP
Palo Alto, CA 
ANALYST COVERAGE
FirmAnalystPhone
Caris & CompanyJames Molloy617-728-0712
Merriman Curhan FordMichael  G. King, Jr.646-292-1424
MultiTrade SecuritiesGary Hobbib212-671-1920
Roth CapitalScott Henry949-720-7123
Zacks Investment ResearchJason Napodano312-265-9421

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.